Friday's UK broker ratings

Updated every day, our UK broker ratings identify which FTSE- and AIM-listed companies are affected by a ratings change.

Listed below are details of selected companies that have undergone a ratings change today. Alternatively, download the pdf to see a full list of today's UK broker ratings.

UK broker ratings (11KB)


Pdfs require Adobe Reader, which is available free from  Adobe.

 

Maintain

Company

Rating

Target price

Potential upside/Downside

Contributing broker

Pearson Outperform 1600 24.3% Exane BNP Paribas
Unilever Overweight 2900 22.6% Barclays
British American Tobacco Overweight 3950 22.6% Barclays

 

New rating

Company

Rating

Target price

Potential upside/Downside

Contributing broker

Diploma Overweight 715 15.8% Barclays
Aggreko Sell 1237 -16.5% Canaccord Genuity Corp

 

Downgrade

Company

Rating

Target price

Potential upside/Downside

Contributing broker

Chemring Neutral 260 11.5% JPMorgan
Croda International Hold 2480 -2.4% Liberum Capital Ltd

 

Source: Bloomberg (11 October 2013)

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.